IQVIA艾昆纬：2025年药物创新的时序演进：首次获批后的扩展频率、时机与临床价值评估报告（英文版）

The Inflation Reduction Act (IRA), enacted in August 2022, includes several measures aimed at reducing government drug spending and improving medication accessibility. A key provision of the IRA is the Medicare Drug Price Negotiation Program, which gives the Centers for Medicare & Medicaid Services (CMS) new authority to set maximum fair prices for certain high-spend drugs. Generally, small molecule drugs that have had market approval for at least 7 years and biologic drugs that have had approva